Randomised comparative study of the immunogenicity of modified intradermal post-exposure rabies vaccine regimens
Ly-Mee Yu with Mary Warrell (Oxford Vaccine Group)
Worldwide about 10 million people each year receive rabies vaccine after exposure, usually by a dog bite, to the risk of contracting rabies. However, these highly priced vaccines impose a high economic burden for many developing countries and many cases subsequently die due to not being able to afford the vaccine, or lack of availability. In Asian and African countries, there is a desperate need for effective, safe and economical rabies vaccine for post-exposure prophylaxis. This randomised non-inferiority trial compares the immunogenicity of two new intradermal regimens, in volunteers, with two reference regimens. Target sample size is 220. Recruitment commenced in 2000.
Ly-Mee Yu with Mary Warrell (Oxford Vaccine Group)
Worldwide about 10 million people each year receive rabies vaccine after exposure, usually by a dog bite, to the risk of contracting rabies. However, these highly priced vaccines impose a high economic burden for many developing countries and many cases subsequently die due to not being able to afford the vaccine, or lack of availability. In Asian and African countries, there is a desperate need for effective, safe and economical rabies vaccine for post-exposure prophylaxis. This randomised non-inferiority trial compares the immunogenicity of two new intradermal regimens, in volunteers, with two reference regimens. Target sample size is 220. Recruitment commenced in 2000.
